نتائج البحث - Nagah Elmusharaf

  • يعرض 1 - 2 نتائج من 2
تنقيح النتائج
  1. 1
    Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial

    Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a mult... حسب Peter Hillmen, Alexandra Pitchford, Adrian Bloor, Angus Broom, Moya Young, Ben Kennedy, Renata Walewska, Michelle Furtado, Gavin Preston, Jeffrey R Neilson, Nicholas Pemberton, Gamal Sidra, Nicholas Morley, Kate Cwynarski, Anna Schuh, Francesco Forconi, Nagah Elmusharaf, Shankara Paneesha, Christopher P. Fox, Dena Howard, Anna Hockaday, Julia Brown, David A. Cairns, Sharon Jackson, Natasha Greatorex, Nichola Webster, Jane Shingles, Surita Dalal, Piers Patten, David Allsup, Andy C. Rawstron, Talha Munir

    منشور في 2023
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease

    Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease حسب Talha Munir, David A. Cairns, Adrian Bloor, David Allsup, Kate Cwynarski, Andrew R. Pettitt, Shankara Paneesha, Christopher P. Fox, Toby A. Eyre, Francesco Forconi, Nagah Elmusharaf, Ben Kennedy, John G. Gribben, Nicholas Pemberton, Oonagh Sheehy, Gavin Preston, Anna Schuh, Renata Walewska, Lelia Duley, Dena Howard, Anna Hockaday, Sharon Jackson, Natasha Greatorex, Sean Girvan, Sue Bell, Julia Brown, Nichola Webster, Surita Dalal, Ruth de Tute, Andy C. Rawstron, Piers Patten, Peter Hillmen

    منشور في 2023
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: